EUVIMEDEUVIMED entdecken
Crossref

Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions

H Joshua Posen iD, Waison Wong, Daniel S Farrar, Aaron Campigotto, Tiffany Chan, Kevin R Barker, Stefan H F Hagmann, Edward T Ryan, Regina C LaRocque, Ashlee M Earl, Colin J Worby, Francesco Castelli und 5 weitere

Journal of Travel Medicine · 2023

DOI: 10.1093/jtm/taac086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Travel Medicine, 2023. Verfasst von H Joshua Posen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Division of Infectious Diseases, Hospital for Sick Children, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Typhoid Fever, Anti-Infective Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Cooperative Agreement, NCEZID CDC HHS, Global Surveillance Network of the International Society of Travel Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extensively drug-resistant (XDR) typhoid fever is a threat to travelers to Pakistan. We describe a multicontinental case series of travel-acquired XDR typhoid fever to demonstrate the global spread of the problem and encourage preventive interventions as well as appropriate empiric antimicrobial use.

Methods

Cases were extracted from the GeoSentinel database, microbiologic laboratory records of two large hospitals in Toronto, Canada, and by invitation to TropNet sites. All isolates were confirmed XDR Salmonella enterica serovar Typhi (Salmonella typhi), with resistance to ampicillin, ceftriaxone, ciprofloxacin and trimethoprim–sulfamethoxazole.

Results

Seventeen cases were identified in Canada (10), USA (2), Spain (2), Italy (1), Australia (1) and Norway (1). Patients under 18 years represented 71% (12/17) of cases, and all patients travelled to Pakistan to visit friends or relatives. Only one patient is known to have been vaccinated. Predominant symptoms were fever, abdominal pain, vomiting and diarrhoea. Antimicrobial therapy was started on Day 1 of presentation in 75% (12/16) of patients, and transition to a carbapenem or azithromycin occurred a median of 2 days after blood culture was drawn. Antimicrobial susceptibilities were consistent with the XDR S. typhi phenotype, and whole genome sequencing on three isolates confirmed their belonging to the XDR variant of the H58 clade.

Conclusions

XDR typhoid fever is a particular risk for travelers to Pakistan, and empiric use of a carbapenem or azithromycin should be considered. Pre-travel typhoid vaccination and counseling are necessary and urgent interventions, especially for visiting friends and relatives travelers. Ongoing sentinel surveillance of XDR typhoid fever is needed to understand changing epidemiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Typhoid FeverAnti-Infective AgentsHumansTravelAzithromycinAnti-Bacterial AgentsSalmonella typhiCarbapenemsPakistan

Stichwörter der Autor:innen

PakistanTyphoid feverantimicrobial resistancereturned travelertravel-acquired infection

Substanzen

AzithromycinAnti-Bacterial AgentsAnti-Infective AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Paediatrics, Division of Infectious Diseases, Hospital for Sick Children, Toronto, ON, Canada.
  • Department of Paediatric Infectious Diseases and Immunology, Alder Hey Children's Hospital, Liverpool, UK.
  • Centre for Global Child Health, Hospital for Sick Children, Toronto, ON, Canada.
  • Department of Paediatric Laboratory Medicine, Division of Microbiology, Hospital for Sick Children, Toronto, ON, Canada.
  • Division of Infectious Diseases, Trillium Health Partners, Mississauga, ON, Canada.
  • Division of Microbiology, Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, ON, Canada.

ORCID-Profile: H Joshua Posen, Michael Libman

Förderung

  • Cooperative Agreement
  • NCEZID CDC HHS
  • Global Surveillance Network of the International Society of Travel Medicine
  • ACL HHS
  • Public Health Agency of Canada

Zitieren

APA

Posen, H. J., Wong, W., Farrar, D. S., Campigotto, A., Chan, T., Barker, K. R., Hagmann, S. H. F., Ryan, E. T., LaRocque, R. C., Earl, A. M., Worby, C. J., Castelli, F., Fumadó, V. P., Britton, P. N., Libman, M., Hamer, D. H., & Morris, S. K. (2023). Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taac086

Vancouver

Posen HJ, Wong W, Farrar DS, Campigotto A, Chan T, Barker KR, et al. Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. Journal of Travel Medicine. 2023. doi:10.1093/jtm/taac086

BibTeX
@article{Posen2023,
  author = {Posen, H Joshua and Wong, Waison and Farrar, Daniel S and Campigotto, Aaron and Chan, Tiffany and Barker, Kevin R and Hagmann, Stefan H F and Ryan, Edward T and LaRocque, Regina C and Earl, Ashlee M and Worby, Colin J and Castelli, Francesco and Fumadó, Victoria Pérez and Britton, Philip N and Libman, Michael and Hamer, Davidson H and Morris, Shaun K},
  title = {Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions},
  journal = {Journal of Travel Medicine},
  year = {2023},
  doi = {10.1093/jtm/taac086}
}
Kostenlos starten →